167 related articles for article (PubMed ID: 37946262)
21. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
22. Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research.
Schoettler ML; Carreras E; Cho B; Dandoy CE; Ho VT; Jodele S; Moissev I; Sanchez-Ortega I; Srivastava A; Atsuta Y; Carpenter P; Koreth J; Kroger N; Ljungman P; Page K; Popat U; Shaw BE; Sureda A; Soiffer R; Vasu S
Transplant Cell Ther; 2023 Mar; 29(3):151-163. PubMed ID: 36442770
[TBL] [Abstract][Full Text] [Related]
23. Eculizumab in Transplant-Associated Thrombotic Microangiopathy.
Dhakal P; Giri S; Pathak R; Bhatt VR
Clin Appl Thromb Hemost; 2017 Mar; 23(2):175-180. PubMed ID: 26259912
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.
Jodele S; Davies SM; Lane A; Khoury J; Dandoy C; Goebel J; Myers K; Grimley M; Bleesing J; El-Bietar J; Wallace G; Chima RS; Paff Z; Laskin BL
Blood; 2014 Jul; 124(4):645-53. PubMed ID: 24876561
[TBL] [Abstract][Full Text] [Related]
25. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
[TBL] [Abstract][Full Text] [Related]
26. Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians.
Nusrat S; Davis H; MacDougall K; George JN; Nakamura R; Borogovac A
J Intensive Care Med; 2024 May; 39(5):406-419. PubMed ID: 37990516
[TBL] [Abstract][Full Text] [Related]
27. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy.
Epperla N; Hemauer K; Hamadani M; Friedman KD; Kreuziger LB
Transfusion; 2017 Nov; 57(11):2775-2781. PubMed ID: 28836275
[TBL] [Abstract][Full Text] [Related]
28. High-dose Carboplatin/Etoposide/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma.
Jodele S; Dandoy CE; Myers K; Wallace G; Lane A; Teusink-Cross A; Weiss B; Davies SM
Bone Marrow Transplant; 2018 Oct; 53(10):1311-1318. PubMed ID: 29674658
[TBL] [Abstract][Full Text] [Related]
29. Approaching treatment of transplant-associated thrombotic Microangiopathy from two directions with Eculizumab and transitioning from Tacrolimus to Sirolimus.
Jan AS; Hosing C; Aung F; Yeh J
Transfusion; 2019 Nov; 59(11):3519-3524. PubMed ID: 31587288
[TBL] [Abstract][Full Text] [Related]
30. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
[TBL] [Abstract][Full Text] [Related]
31. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
Wright RD; Bannerman F; Beresford MW; Oni L
BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
[TBL] [Abstract][Full Text] [Related]
32. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients.
Jodele S; Sabulski A
Expert Rev Hematol; 2021 Aug; 14(8):751-763. PubMed ID: 34301169
[TBL] [Abstract][Full Text] [Related]
33. Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
Alhomoud M; Williams A; Magro C; Van Besien K; Vesole DH; Laurence J
Leuk Lymphoma; 2022 Feb; 63(2):473-477. PubMed ID: 34668824
[No Abstract] [Full Text] [Related]
34. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?
Dhakal P; Bhatt VR
Bone Marrow Transplant; 2017 Mar; 52(3):352-356. PubMed ID: 27775697
[TBL] [Abstract][Full Text] [Related]
35. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.
Canaud G; Kamar N; Anglicheau D; Esposito L; Rabant M; Noël LH; Guilbeau-Frugier C; Sberro-Soussan R; Del Bello A; Martinez F; Zuber J; Rostaing L; Legendre C
Am J Transplant; 2013 Aug; 13(8):2179-85. PubMed ID: 23763583
[TBL] [Abstract][Full Text] [Related]
36. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy.
Bohl SR; Kuchenbauer F; von Harsdorf S; Kloevekorn N; Schönsteiner SS; Rouhi A; Schwarzwälder P; Döhner H; Bunjes D; Bommer M
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2172-2177. PubMed ID: 28860002
[TBL] [Abstract][Full Text] [Related]
37. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab.
Shochet L; Kanellis J; Simpson I; Ta J; Mulley W
Nephrology (Carlton); 2017 Feb; 22 Suppl 1():23-27. PubMed ID: 28176480
[TBL] [Abstract][Full Text] [Related]
38. Early Increase in Complement Terminal Pathway Activation Marker sC5b-9 Is Predictive for the Development of Thrombotic Microangiopathy after Stem Cell Transplantation.
Horváth O; Kállay K; Csuka D; Mező B; Sinkovits G; Kassa C; Stréhn A; Csordás K; Sinkó J; Prohászka Z; Kriván G
Biol Blood Marrow Transplant; 2018 May; 24(5):989-996. PubMed ID: 29339271
[TBL] [Abstract][Full Text] [Related]
39. A Heterozygous CFHR3-CFHR1 Gene Deletion in a Pediatric Patient With Transplant-associated Thrombotic Microangiopathy Who was Treated With Eculizumab.
Nozawa A; Ozeki M; Hori T; Kawamoto N; Hirayama M; Azuma E; Fukao T
J Pediatr Hematol Oncol; 2018 Nov; 40(8):e544-e546. PubMed ID: 28991129
[TBL] [Abstract][Full Text] [Related]
40. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study.
Menne J; Delmas Y; Fakhouri F; Licht C; Lommelé Å; Minetti EE; Provôt F; Rondeau E; Sheerin NS; Wang J; Weekers LE; Greenbaum LA
BMC Nephrol; 2019 Apr; 20(1):125. PubMed ID: 30971227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]